Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Orphazyme begins dosing patients in phase III AIDNPC interventional study

June 20, 2016

Poxel advances phase I trial of direct AMPK activator PXL-770

June 20, 2016

Kissei Pharmaceutical launches Glufast orally disintegrating tablets in Japan

June 17, 2016

RPC-8844 demonstrates promising efficacy in mouse models of type 2 diabetes

June 17, 2016

TASP-0434299: a specific radioligand to vasopressin V1B receptor

June 16, 2016

Merck & Co. announces OX2 receptor antagonists

June 16, 2016

Bone Biologics signs agreement with UCLA to license Nell-1 for osteoporosis

June 16, 2016

Wanbang Biopharmaceuticals to prepare IND application for SBM-TFC-039

June 14, 2016

Merck & Co. discloses OX2 receptor antagonists

June 14, 2016

Gla-300: meta-analysis of EDITION -1, -2 and -3 studies

June 13, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...